Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany
- Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany
- Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicines
- New penicillin production process will significantly improve ecological footprint and help secure European-based supply
- Cutting-edge development hub will play key role in supporting long-term growth of leading biosimilar business
Basel – Sandoz, the global leader in generic and biosimilar medicines, has opened two new European facilities, in line with its ongoing plans to strengthen sustainable development and supply of critical medicines in Europe and beyond.
The inauguration of a new facility for production of penicillin at Kundl, Austria, and a new biosimilar development center in Holzkirchen, Germany, reaffirm the dual Sandoz commitment to ensuring sustainable access to quality antibiotics and spearheading development of biosimilars.
Sandoz has the only major remaining vertically-integrated production network for penicillins in Europe; penicillins are the leading category of antibiotics worldwide. The EUR 150 million Kundl investment, which includes a contribution of EUR 50 million from the Austrian federal government, represents a significant upgrade of penicillin API (active pharmaceutical ingredient) manufacturing.
Richard Saynor, CEO Sandoz said: "These investments strengthen our industrial presence in Europe, reinforce our commitment to environmental responsibility, and reaffirm our determination to be the world's leading and most valued generics and biosimilars company. Antibiotics are the backbone of modern medicine and the Kundl plant is a testament to the resilience of European manufacturing. The new development center in Holzkirchen will become a global hub for biosimilar expertise."
The EUR 25 million Holzkirchen investment will pave the way for the German site to become the leading Sandoz analytical characterization center for biosimilars.
The Austrian federal and Bavarian state governments have been highly supportive of these projects, recognizing their importance for ensuring availability of medicines and advancing medical research in Europe.
Latest news
Arkema and ProLogium enter cooperation for next-generation lithium-ceramic battery materials for e-mobility with the construction of a gigafactory in Dunkirk, France
Arkema has been chosen by ProLogium, a Taiwanese technology leader in advanced batteries, as a key development and supply partner ahead of the launch of its gigafactory in France.
MOL inaugurated €1.3 billion polyol complex in Tiszaújváros, Hungary
The €1.3 billion project is MOL's largest organic investment to date, for which it has also received support from the Hungarian state. Thanks to technology of thyssenkrupp Uhde and Evonik, the plan...
BASF invests in capacity expansion of Basoflux® range of paraffin inhibitors in Tarragona, Spain.
BASF Tarragona →Increased production at the BASF site in Tarragona, Spain to support growing global demand for high-quality paraffin inhibitor chemistries. Investment reinforces BASF’s commitment to innovative and...
LYB to build integrated plastic waste recycling hub in Chemiepark Knapsack, Germany
Chemiepark Knapsack →The hub is planned to combine various advanced sorting and recycling operations, helping to address the plastic waste challenge and grow the circular economy